Cronos Group Inc, formerly known as PharmaCan Capital Corp., is a principal investment firm. The firm seeks to invest in companies either licensed, or actively seeking a license, to produce medical marijuana pursuant to Canada's Marihuana for Medical Purposes Regulations MMPR. The firm typically invests in companies based in Canada. The firm is primarily an equity investor, may also advance debt as appropriate.
Read More…
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone416-504-0004
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesC$26.07 million
Profitability
Miscellaneous
Employees291
Next Earnings DateN/A
OptionableOptionable
Cronos Group (TSE:CRON) Frequently Asked Questions
What is Cronos Group's stock symbol?
Cronos Group trades on the Toronto Stock Exchange (TSX) under the ticker symbol "CRON."
What price target have analysts set for CRON?
6 brokers have issued 12 month target prices for Cronos Group's stock. Their forecasts range from C$15.00 to C$29.00. On average, they anticipate Cronos Group's stock price to reach C$22.63 in the next twelve months. This suggests a possible upside of 42.6% from the stock's current price. View Analyst Price Targets for Cronos Group.
What is the consensus analysts' recommendation for Cronos Group?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cronos Group in the last year. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Cronos Group.
Has Cronos Group been receiving favorable news coverage?
Media coverage about CRON stock has trended negative on Monday, according to InfoTrie Sentiment. The research group scores the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Cronos Group earned a coverage optimism score of -2.3 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Cronos Group.
Who are some of Cronos Group's key competitors?
Some companies that are related to Cronos Group include ProMetic Life Sciences (PLI), MorphoSys (MOR), MorphoSys (MOR), BTG (BTG), Asterias Biotherapeutics (AST), Abcam (ABC), Genus (GNS), Concordia International (CXR), Clinuvel Pharmaceuticals (CUV), Polynovo (PNV), Mesoblast (MSB), Resverlogix (RVX), Oxford BioMedica (OXB), Neptune Wellness Solutions (NEPT) and Starpharma (SPL).
What other stocks do shareholders of Cronos Group own?
Who are Cronos Group's key executives?
Cronos Group's management team includes the folowing people:
- Mr. Michael Gorenstein, Chairman, Pres & CEO (Age 31)
- Mr. David Hsu, Chief Operating Officer
- Ms. Xiuming Shum, Gen. Counsel & Corp. Sec.
- Mr. Jeffrey Jacobson, Head of Sales & Bus. Devel.
- Mr. William Hilson, Chief Commercial Officer
How do I buy shares of Cronos Group?
Shares of CRON and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Cronos Group's stock price today?
One share of CRON stock can currently be purchased for approximately C$15.87.
How big of a company is Cronos Group?
What is Cronos Group's official website?
How can I contact Cronos Group?
The company can be reached via phone at 416-504-0004.
MarketBeat Community Rating for Cronos Group (TSE CRON)
MarketBeat's community ratings are surveys of what our community members think about Cronos Group and other stocks. Vote "Outperform" if you believe CRON will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRON will underperform the S&P 500 over the long term. You may vote once every thirty days.
